{Reference Type}: Journal Article
{Title}: Temporal and spatial heterogeneity of HER2 status in metastatic colorectal cancer.
{Author}: D'Angelo F;Monnien F;Overs A;Pem I;Dor F;Abad M;Felix S;Selmani Z;Lakkis Z;Borg C;Doussot A;Bibeau F;Molimard C;
{Journal}: Diagn Pathol
{Volume}: 19
{Issue}: 1
{Year}: 2024 Jun 22
{Factor}: 3.196
{DOI}: 10.1186/s13000-024-01508-y
{Abstract}: <B>BACKGROUND: </B>HER2-targeted therapies have recently emerged as an option in the management of metastatic colorectal cancer (mCRC) overexpressing HER2. However, data regarding HER2 status in primary CRC and its corresponding liver metastases are limited, potentially influencing clinical decisions. Therefore, the aim of this study was to compare the HER2 status in primary CRC and paired liver metastases.<BR><B>METHODS: </B>Patients with mCRC who were operated from their primary colorectal cancer and their corresponding synchronous or metachronous liver metastases, in the digestive surgery department of Besançon University Hospital, between April 1999 and October 2021, were included. Tissue microarrays were constructed from matched primary CRC and liver metastastic tissue samples. HER2 status was assessed by immunohistochemistry and in situ hybridization according to Valtorta's criteria.<BR><B>RESULTS: </B>A series of 108 paired primary CRC and liver metastases, including a series of multiple liver metastases originating from the same patients (n = 24), were assessed. Among the primary CRC, 89 (82.4%), 17 (15.8%) and 2 (1.8%) cases were scored 0, 1 + and 2 + respectively. In liver metastases, 99 (91.7%), 7 (6.5%) and 2 (1.8%) were scored 0, 1 + and 2, respectively. Overall, there was a 19% discrepancy rate in HER2 status between primary CRC and metastases, which increased to 21% in cases with multiple synchronous or metachronous liver metastases in a given patient. No significant difference was found between metachronous and synchronous metastases regarding the HER2 status (p = 0.237).<BR><B>CONCLUSIONS: </B>Our study highlights the temporal and spatial heterogeneity of HER2 status between primary CRC and corresponding liver metastases. These findings raise the question of a sequential evaluation of the HER2 status during disease progression, to provide the most suitable treatment strategy.